Authors

Claudine Isaacs, MD is Professor of Medicine and Oncology and Associate Director for Clinical Research at the Lombardi Comprehensive Cancer Center.

Latest:

Dr Isaacs on Establishing Consensus on DESTINY-Breast09 Data in HER2+ Metastatic Breast Cancer

Claudine Isaacs, MD, discusses how to integrate data from the phase 3 DESTINY-Breast09 trial into the HER2-positive metastatic breast cancer paradigm.

Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center

Latest:

Decision Factors for SubQ Therapy and Unmet Needs

Claudine J. Isaacs, MD, Lombardi Comprehensive Cancer Center

Claudio Anasetti, MD

Latest:

Dr. Anasetti Discusses the Trade-offs of BMT and PBSC

Dr. Claudio Anasetti from the H. Lee Moffitt Cancer Center Discusses the Trade-offs of BMT and PBSC

Claus-Henning KÃ¶hne, MD, PhD, Klinikum Oldenburg

Clayton S. Lau, MD

Latest:

Dr. Lau on Controversies Surrounding Prostate Cancer Screening

Clayton S. Lau, MD, director, Urologic Oncology, director, Robotic Surgery, Prostate Cancer Surgery, interim chair of Urology, City of Hope, discusses the controversies surrounding prostate cancer screening. Lau spoke on this in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

Clemens A. Schmitt, MD

Latest:

Dr. Schmitt on a Novel Treatment Approach to Hodgkin Lymphoma

Clemens A. Schmitt, MD, director and professor at Berlin School of Integrative Oncology, discusses a conceptually novel treatment approach to classical Hodgkin lymphoma.

Clemens Krepler, MD

Latest:

Patient-Derived Xenograft (PDX) Models as Avatars for Patient Response to Therapy

The promise of personalized medicine in cancer will only be met once physicians have both the arsenal of therapeutics they need and a more complete understanding of genomic tumor profiles.

Clifford A. Hudis, MD

Latest:

Dr. Hudis on Combating Obesity in Breast Cancer

Clifford A. Hudis, MD, CEO, ASCO, discusses how oncologists should be helping patients with breast cancer overcome obesity.

Clinical Consulting, ION Solutions, a part of AmerisourceBergen

Latest:

What Oncologists Need to Know About USP and the Recent Clarification

Patients with cancer across the country rely on community oncology practices to provide them with high-quality, coordinated cancer care.

Colin G. Evans, PhD

Latest:

Preventing and Treating Bone Metastases in mCRPC

Bone metastases in metastatic castration-resistant prostate cancer can invade a range of sites in the skeleton where they precipitate a spectrum of pathological processes that increase morbidity, negatively affect quality of life, and decrease survival.

Colleen M. Danielson, NP, Massachusetts General Hospital

Colleen OLeary, MSN

Latest:

Colleen O'Leary Describes Chemotherapy Safety

Colleen OLeary from James Cancer Hospital Describes Chemotherapy Safety Standards

Colleen S. Delaney, MD, MSC

Latest:

No Need to Wait for the Perfect Match-Cord Blood Is Saving Time and Lives

The perception that cord blood is an inferior source of stem cells is simply not accurate and may result in delays in lifesaving treatment for patients.

Conleth Murphy, MD

Latest:

The Year in Breast Cancer: The Top Five Under-appreciated Developments of 2008

Connie Batlevi, MD

Latest:

Dr. Batlevi on the Role of Active Surveillance in Advanced-Stage Follicular Lymphoma

Connie L. Batlevi, MD, PhD, discusses the role of active surveillance in advanced-stage follicular lymphoma.

Connie Lehman, MD, PhD

Latest:

10 Tips for Breast Cancer Screening and Early Detection

Early detection offers the best chance for a cure.

Connor Liu

Latest:

The Importance of Combination Immune Therapy in Orthotopic Murine Glioblastoma

Connor Liu, medical student, Washington University School of Medicine, discusses the importance of combination immunotherapy in orthotopic murine glioblastoma.

Conor Killmurray

Latest:

Mirvetuximab Soravtansine Associated With Improved HRQOL in FRα+ Ovarian Cancer

Mirvetuximab soravtansine improved health-related quality of life in patients with FRα-positive, platinum-resistant ovarian cancer.

Conor Lynch, PhD

Latest:

Biology of Bone Metastases in Patients With mCRPC

Conor Lynch, PhD, an associate professor of Tumor Biology at Moffitt Cancer Center, discusses the biology of bone metastases in patients with castration-resistant prostate cancer.